Basic Information
| Drug ID | DDPD00238 |
|
| Drug Name | Nevirapine | |
| Molecular Weight | 266.2979 | |
| Molecular Formula | C15H14N4O | |
| CAS Number | 129618-40-2 | |
| SMILES | CC1=C2NC(=O)C3=C(N=CC=C3)N(C3CC3)C2=NC=C1 | |
| External Links | ||
| DRUGBANK | DB00238 | |
| PubChem Compound | 4463 | |
| PDR | 1423 | |
| Drugs.com | Drugs.com Drug Page | |
Experimental Physicochemical Property
| Property Name | Property Value | Unit | Raw Value | Raw Unit | Reference |
|---|---|---|---|---|---|
| Caco-2 Permeability | -4.52 | - | -4.52 | - | ADME Research, USCD |
| Log P | 2.5 | - | 2.5 | - | DRUGBANK |
| Melting Point | 196.06 | ℃ | 196.06 | ℃ | DRUGBANK |
| Water Solubility | 0.7046 | mg/L | 0.7046 | mg/L | DRUGBANK |
Pharmacokinetic/ Toxicokinetic Property
| Property Name | Property Value | Unit | Raw Value | Raw Unit | Annotation | Factor | Reference |
|---|---|---|---|---|---|---|---|
| Absorption | 90.0 | % | >90 | % | PO, oral; normal,healthy; AIDS,HIV; | DRUGBANK | |
| Bioavailability | 93.0 | % | 93±9 | % | normal,healthy; adults; | DRUGBANK | Bioavailability | 91.0 | % | 91±8 | % | normal,healthy; adults; | DRUGBANK | Bioavailability | 93.0 | % | 93±9 | % | PO, oral; | The Pharmacological Basis of Therapeutics |
| C Max | 2000.0 | ng/ml | 2±0.4 | mcg/ml | PO, oral; | DRUGBANK | C Max | 2000.0 | ng/ml | 2±0.4 | mcg/ml | Oral single dose; adults; AIDS,HIV; | The Pharmacological Basis of Therapeutics | C Max | 4500.0 | ng/ml | 4.5±1.9 | mcg/ml | Oral multiple dose; adults; AIDS,HIV; | The Pharmacological Basis of Therapeutics |
| T Max | 4.0 | h | 4 | h | PO, oral; | DRUGBANK | T Max | 3.0 | h | 2-4 | h | The Pharmacological Basis of Therapeutics |
| Clearance | 0.0300 | L/h/kg | 0.23-0.77 | ml/min/kg | apparent clearance; Single dose; | The Pharmacological Basis of Therapeutics | Clearance | 0.0534 | L/h/kg | 0.89 | ml/min/kg | apparent clearance; Multiple dose; | Children ↑ ; | The Pharmacological Basis of Therapeutics | Clearance | 0.0180 | L/h/kg | 0.3 | ml/min/kg | intravenous injection, IV; human, homo sapiens; | Human Intravenous Pharmacokinetic Dataset |
| Volume of Distribution | 1.2 | L/kg | 1.21±0.09 | L/kg | intravenous injection, IV; normal,healthy; adults; | DRUGBANK | Volume of Distribution | 1.2 | L/kg | 1.2±0.09 | L/kg | The Pharmacological Basis of Therapeutics | Volume of Distribution | 1.2 | L/kg | 1.2 | L/kg | The Pharmacological Basis of Therapeutics | Volume of Distribution | 1.3 | L/kg | 1.3 | L/kg | intravenous injection, IV; human, homo sapiens; | Human Intravenous Pharmacokinetic Dataset |
| Half-life | 45.0 | h | 45 | h | DRUGBANK | Half-life | 45.0 | h | 45.0 | h | Single dose; | The Pharmacological Basis of Therapeutics | Half-life | 30.0 | h | 25-35 | h | Multiple dose; | The Pharmacological Basis of Therapeutics | Half-life | 53.0 | h | 53 | h | intravenous injection, IV; human, homo sapiens; | Human Intravenous Pharmacokinetic Dataset |
| Eliminate Route | 3.0 | % | <3 | % | Urinary excretion; adults; normal,healthy; AIDS,HIV; human, homo sapiens; Unchanged drug; | The Pharmacological Basis of Therapeutics | |
| Protein Binding | 60.0 | % | 60 | % | plasma proteins; | DRUGBANK | Protein Binding | 60.0 | % | 60 | % | adults; normal,healthy; AIDS,HIV; human, homo sapiens; | The Pharmacological Basis of Therapeutics |
Maximum Dosage
| Property Name | Property Value | Unit | Raw Value | Raw Unit | Annotation | Brand Name | Component | Reference |
|---|---|---|---|---|---|---|---|---|
| Max dose for neonates | 12.0 | mg/kg/day | 12 | mg/kg/day | PO, oral | Viramune XR | nevirapine | PDR |
| Max dose for neonates | 300.0 | mg/m2/day | 300 | mg/m2/day | PO, oral | Viramune XR | nevirapine | PDR |
| Max dose for neonates | 12.0 | mg/kg/day | 12 | mg/kg/day | PO, oral | Viramune XR | nevirapine | PDR |
| Max dose for neonates | 8.0 | mg/day | 8 | mg/day | PO, oral | Viramune XR | nevirapine | PDR |
| Max dose for neonates | 12.0 | mg/day | 12 | mg/day | PO, oral | Viramune XR | nevirapine | PDR |
| Max dose for neonates | 12.0 | mg/kg/day | 12 | mg/kg/day | PO, oral | Viramune XR | nevirapine | PDR |
| Max dose for neonates | 8.0 | mg/kg/day | 8 | mg/kg/day | PO, oral | Viramune XR | nevirapine | PDR |
| Max dose for infants | 12.0 | mg/kg/day | 12 | mg/kg/day | PO, oral | Viramune XR | nevirapine | PDR |
| Max dose for infants | 300.0 | mg/m2/day | 300 | mg/m2/day | PO, oral | Viramune XR | nevirapine | PDR |
| Max dose for children | 300.0 | mg/m2/day | 300 | mg/m2/day | PO, oral | Viramune XR | nevirapine | PDR |
| Max dose for children | 400.0 | mg/day | 400 | mg/day | Tablet,PO，oral | Viramune XR | nevirapine | PDR |
| Max dose for children | 300.0 | mg/m2/day | 300 | mg/m2/day | PO, oral | Viramune XR | nevirapine | PDR |
| Max dose for children | 400.0 | mg/m2/day | 400 | mg/m2/day | PO, oral | Viramune XR | nevirapine | PDR |
| Max dose for children | 300.0 | mg/m2/day | 300 | mg/m2/day | PO, oral | Viramune XR | nevirapine | PDR |
| Max dose for children | 400.0 | mg/day | 400 | mg/day | Tablet,PO，oral | Viramune XR | nevirapine | PDR |
| Max dose for children | 400.0 | mg/m2/day | 400 | mg/m2/day | PO, oral | Viramune XR | nevirapine | PDR |
| Max dose for children | 300.0 | mg/m2/day | 300 | mg/m2/day | PO, oral | Viramune XR | nevirapine | PDR |
| Max dose for children | 400.0 | mg/m2/day | 400 | mg/m2/day | PO, oral | Viramune XR | nevirapine | PDR |
| Max dose for children | 300.0 | mg/m2/day | 300 | mg/m2/day | PO, oral | Viramune XR | nevirapine | PDR |
| Max dose for adolescents | 300.0 | mg/m2/day | 300 | mg/m2/day | PO, oral | Viramune XR | nevirapine | PDR |
| Max dose for adolescents | 400.0 | mg/day | 400 | mg/day | Tablet,PO，oral | Viramune XR | nevirapine | PDR |
| Max dose for adolescents | 300.0 | mg/m2/day | 300 | mg/m2/day | PO, oral | Viramune XR | nevirapine | PDR |
| Max dose for adults | 400.0 | mg/day | 400 | mg/day | PO, oral | Viramune XR | nevirapine | PDR |
| Max dose for geriatric | 400.0 | mg/day | 400 | mg/day | PO, oral | Viramune XR | nevirapine | PDR |
Drug Property Radar Chart
Note: Center: Q1-1.5*IQR, Edge: Q3+1.5*IQR; Q1: Quantile 1, Q3: Quantile 3, IQR: Q3-Q1